Trevi Therapeutics 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Good morning, everyone, and welcome to the Trevi Therapeutics session. Happy to have Jennifer Good, CEO of Trevi, with us, as well as Dave Hastings, CFO. As you know, Trevi is now the solo operator in the chronic cough indication.
Who would have guessed, right?
Who would have guessed after all these years? It's a good position to be in. Jennifer, why don't you give us a quick overview, lay of the land, and then we can launch into questions.
Sounds good. First of all, Annabel, thanks to Stifel for hosting us. They've been a good longtime partner of ours at the company, and thank you for you guys for coming to our talk. Trevi is a simple company. We're a single-asset company that is focused in three different chronic cough indications: chronic cough and IPF, chronic cough and other interstitial lung diseases, and refractory chronic cough. I know some of you have followed this field for a while. They're very big unmet needs, and a lot of companies have come and gone through this space. I think we came into this space with sort of a different approach, which we'll probably talk a bit about, but we basically were treating cough through the brain as opposed to trying to treat it through the lungs solely.
I think with the benefit of hindsight, that's what at the end of the day, we're all alone in these three big market indications. We are in phase III in our lead indication. We've aligned with the FDA, and 2027's a year with a lot of data ahead, so I'm excited about the future.
Fantastic. Why don't we just get the SSRE out of the way?
Because that's been a topic- Haven't had that question before.
has been a topic on everyone's mind.
Call participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
